Mediphage Bioceuticals is a genetic medicine company spun out of the University of Waterloo in Canada, focused on developing SAFE, EFFECTIVE, and ACCESSIBLE gene delivery platforms to unlock the therapeutic power of personalized, redoseable, genetic medicine.
Mediphage Bioceuticals Inc. was formed as a spin off company from the University of Waterloo in Ontario, Canada.
Mediphage Bioceuticals closes its seed round of 490K to develop proof of concept and perform early stage efficacy studies.
Mediphage Bioceuticals successfully develops its DNA Ministring production and targeting technology. Mediphage also completes early stage concept and efficacy studies.
Mediphage Bioceuticals moves to the MaRS Innovation Center located in Toronto, Ontario. Mediphage Bio is now entering late stage safety and efficacy studies and is beginning to manufacture DNA Ministrings in compliance with cGMP manufacturing practices.
DNA ministrings (msDNA) are an efficient, customizable, and redosable vector for ex vivo and in vivo gene therapies, CAR-T, and CRISPR therapeutic applications.
- Modular, non-viral minivectors that maintain stability due to linear topology and closed-ends
- Produced in 8 hours from bacteriophage elements in E. coli bacteria
- The only vectors capable of protecting from harmful mutations in the chromosome by selectively inducing cell death upon harmful integration
- No immunostimulatory components to enhance repeated administration
With the highest safety profile across viral and non-viral vectors, DNA ministrings enhance the transition of current genetic engineering technology into true personalized genetic medicine.
To date, we have graduated from Creative Destruction Labs West, Illumina Accelerator, Canada-Chicago Mentorship Program (C2MP), and our home base - JLABS@Toronto at MaRS Toronto. Additionally, our technology has also been featured in Nature/Cell-affiliate journals.
Our msDNA is currently being evaluated by therapeutic development partners using gene therapy, CAR-T, DNA vaccines, iPSCs, CRISPR, and B cell immunotherapy approaches across a variety of applications.
If you are interested in evaluating msDNA with your technology, please contact us at email@example.com.
Dr. Roderick Slavcev,
Founder & CEO, HBSc, PhD, MBA, MRSB, C.Biol
Associate Professor, Pharmaceutical Sciences
Professor, Business & Entrepreneurship School of Pharmacy, University of Waterloo
Chartered Biologist, Royal Society of Biology
Senior Scientist, PhD, MSc
B.W. Pearson Research Medal (2014)
University of Waterloo School of Pharmacy Award of Excellence (2013)
Chief Operations Officer
MA - International Relations
BMath - Computer Science (Bioinformatics)